# A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

> **NCT03519308** · EARLY_PHASE1 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT03519308
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-29
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The accrual goal could not be met and the drug manufacturer pulled support
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519308, "A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03519308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*